The prevalence of BK virus infection in De Novo Kidney Transplant Recipients Receiving Mizoribine or Mycophenolic Acid: A Prospective, Randomized, Multicenter Study in China

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-16009202

Enrollment

Unknown

Registered

2016-09-13

Start date

2016-09-15

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney transplantation

Interventions

MZR group:MZR

MMF/EC-MPS group:MMF/EC-MPS

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Recipients between 18 and 60 years age; 2) First kidney transplant recipients; 3) Recipients with weight between 40 and 90 Kg; 4) Recipients are willing to sign informed consent.

Exclusion criteria

Exclusion criteria: 1) Recipients who had been transplanted with Multiorgan; 2) ABO-identical kidney transplantation; 3) Patient with Panel-reactive antibody (PRA) level > 30%; 4) Patient with positive DSA; 5) Patient with sCr >3mg/dL ; 6) Patients who have a history of allergies to any investigational product; 7) Patients with active infections; 8) Patient with white blood cell count <3×10^3/mm3; 9) Women who are pregnant or seeking to become pregnant during the study period; 10) Patient who had received other immunosuppressants (Azathioprine and Tacrolimus, etc.) ; 11) Patient who is unsuitable for participating in this study in the opinion of investigators.

Design outcomes

Primary

Measure	Time frame
BK virus;	—

Countries

China

Contacts

Public ContactYe Tian

Beijing Friendship Hospital, Capital Medical University

tianye166@126.com+86 10-63139040

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026